Inactive Instrument

Highlights IMARA

Equities

IMRA

US45249V1070

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

Enliven Therapeutics Completes Merger With Imara	24/02/23	MT
Enliven Therapeutics, Inc. completed the acquisition of IMARA Inc. from a group of shareholders for approximately $340 million in a reverse merger transaction.	22/02/23	CI
Imara Announces Stockholder Approval of Merger With Enliven	22/02/23	GL
Imara Announces Stockholder Approval of Merger With Enliven	22/02/23	GL
IMARA INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-K)	10/02/23	AQ
IMARA Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	10/02/23	CI
IMARA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Imara Inc. - IMRA	25/01/23	BU
Cardurion Pharmaceuticals, LLC acquired Tovinontrine (IMR-687) and All of the Assets Related to PDE9 Program from IMARA Inc. for approximately $95.	09/11/22	CI
IMARA Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	25/10/22	CI
IMARA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Imara Inc. - IMRA	14/10/22	BU
Arix Bioscience Portfolio Company Imara To Merge With Enliven Therapeutics	14/10/22	MT
IMARA, Enliven Therapeutics to Merge in All-Stock Deal; Shares Rise After Hours	13/10/22	MT
Enliven Therapeutics and Imara Inc Merger Call	13/10/22	FA
Enliven Therapeutics and Imara Announce Merger Agreement	13/10/22	GL
Enliven Therapeutics, Inc. entered into a definitive merger agreement to acquire IMARA Inc. from a group of shareholders in a reverse merger transaction.	12/10/22	CI
Cardurion Pharmaceuticals, LLC entered into an asset purchase agreement to acquire Tovinontrine (IMR-687) and All of the Assets Related to PDE9 Program from IMARA Inc. for approximately $95.	06/09/22	CI
IMARA Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	03/08/22	CI
IMARA Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	06/05/22	CI
Imara Announces Results of Interim Analyses of Tovinontrine (IMR-687) Phase 2b Clinical Trials in Sickle Cell Disease and Beta-Thalassemia	05/04/22	CI
IMARA INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-K)	15/03/22	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights IMARA

Equities

IMRA

US45249V1070

Highlights

Filters